相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia
Issa J. Dahabreh et al.
LEUKEMIA RESEARCH (2009)
JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia
Raymond S. M. Wong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain
Panayiotis D. Ziakas
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
Francesco Passamonti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Leukocytosis and risk stratification assessment in essential thrombocythemia
Alessandra Carobbio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia
Hui-Hua Hsiao et al.
EXPERIMENTAL HEMATOLOGY (2007)
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
Jaya Kittur et al.
CANCER (2007)
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status
Guido Finazzi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Mechanisms of disease: The myeloproliferative disorders
Peter J. Campbell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The paradox of platelet activation and impaired function: Platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera
Jan J. Michiels et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
F Passamonti et al.
BLOOD (2006)
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders
H Quentmeier et al.
LEUKEMIA (2006)
Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
AP Wolanskyj et al.
MAYO CLINIC PROCEEDINGS (2006)
The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia
B Cheung et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia
Andrew I. Schafer
BLOOD (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
R Kralovics et al.
BLOOD (2005)
JAK2V617F mutation in essential thrombocythaemia:: clinical associations and long-term prognostic relevance
AP Wolanskyj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
E Antonioli et al.
LEUKEMIA (2005)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
AV Jones et al.
BLOOD (2005)
Essential thrombocythaemia: challenges and evidence-based management
CN Harrison
BRITISH JOURNAL OF HAEMATOLOGY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
A long-term retrospective study of young women with essential thrombocythemia
A Tefferi et al.
MAYO CLINIC PROCEEDINGS (2001)
分享论文
